scholarly journals 444. A Small Molecule That Inhibits p53 Degradation Influences Cytotoxicity of Ad-p53 in INK4A/ARF-Defective Mesothelioma with Wild-Type p53 Gene

2014 ◽  
Vol 22 ◽  
pp. S170
HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 443-444
Author(s):  
N. Ferrari ◽  
L. Bevan ◽  
J. Castro ◽  
G. Chessari ◽  
L. Fazal ◽  
...  

1997 ◽  
Vol 186 (5) ◽  
pp. 695-704 ◽  
Author(s):  
Michel P.M. Vierboom ◽  
Hans W. Nijman ◽  
Rienk Offringa ◽  
Ellen I.H. van der Voort ◽  
Thorbald van Hall ◽  
...  

The tumor suppressor protein p53 is overexpressed in close to 50% of all human malignancies. The p53 protein is therefore an attractive target for immunotherapy. Cytotoxic T lymphocytes (CTLs) recognizing a murine wild-type p53 peptide, presented by the major histocompatibility complex class I molecule H-2Kb, were generated by immunizing p53 gene deficient (p53 −/−) C57BL/6 mice with syngeneic p53-overexpressing tumor cells. Adoptive transfer of these CTLs into tumor-bearing p53 +/+ nude mice caused complete and permanent tumor eradication. Importantly, this occurred in the absence of any demonstrable damage to normal tissue. When transferred into p53 +/+ immunocompetent C57BL/6 mice, the CTLs persisted for weeks in the absence of immunopathology and were capable of preventing tumor outgrowth. Wild-type p53-specific CTLs can apparently discriminate between p53-overexpressing tumor cells and normal tissue, indicating that widely expressed autologous molecules such as p53 can serve as a target for CTL-mediated immunotherapy of tumors.


2013 ◽  
Vol 20 (4) ◽  
pp. 222-228 ◽  
Author(s):  
E R Camp ◽  
C Wang ◽  
E C Little ◽  
P M Watson ◽  
K F Pirollo ◽  
...  

2001 ◽  
Author(s):  
Koji Endo ◽  
Itaru Kuratate ◽  
Mari Watanabe ◽  
Haruhiko Yoshida ◽  
Ryota Teshima ◽  
...  

2010 ◽  
Vol 16 (4) ◽  
pp. 509-514 ◽  
Author(s):  
Qiang Huang ◽  
Zhibo Xia ◽  
Yongping You ◽  
Peiyu Pu

1992 ◽  
Vol 12 (12) ◽  
pp. 5581-5592 ◽  
Author(s):  
E Shaulian ◽  
A Zauberman ◽  
D Ginsberg ◽  
M Oren

Mutations in the p53 gene are most frequent in cancer. Many p53 mutants possess transforming activity in vitro. In cells transformed by such mutants, the mutant protein is oligomerized with endogenous cell p53. To determine the relevance of oligomerization for transformation, miniproteins containing C-terminal portions of p53 were generated. These miniproteins, although carrying no point mutation, transformed at least as efficiently as full-length mutant p53. Transforming activity was coupled with the ability to oligomerize with wild-type p53, as well as with the ability to abrogate sequence-specific DNA binding by coexpressed wild-type p53. These findings suggest that p53-mediated transformation may operate through a dominant negative mechanism, involving the generation of DNA binding-incompetent oligomers.


Sign in / Sign up

Export Citation Format

Share Document